The Patient Capital Review may be of all-consuming interest to those who work in the tax-advantaged investment sector but, if you are only after a summary of the salient points, Jack Rose is happy to oblige
For those of us who work within the tax-advantaged investment sector, the impending outcome of the Patient Capital Review (PCR) - its possible permutations and consequences - is the talk of the town. But those who spend less time dwelling on tax legislation and rule changes within the sector (very wise if you ask me) are inclined to look blank when you mention the PCR. So for those who like a simple summary of the salient points, here you go. What is it? In November last year, the government announced it would be launching a review into how the UK funds and provides investment capit...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes